Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
Agostino Gemelli University Polyclinic · Chinese Academy of Medical Sciences & Peking Union Medical College · +36 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
343
total citations
- FWCI
- 173.11
- Percentile
- 100%
- References
- 27
Citations per year
Authors
34- DLDomenica LorussoCorresponding
Agostino Gemelli University Polyclinic
- YXYang Xiang
Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital
- KHKosei Hasegawa
Saitama Medical University
- GSGiovanni Scambia
Agostino Gemelli University Polyclinic, Istituti di Ricovero e Cura a Carattere Scientifico
- MLManuel Leiva
Universidad Ricardo Palma
Topics & keywords
Topics
Keywords
- Pembrolizumab
- Medicine
- Placebo
- Cervical cancer
- Chemoradiotherapy
- Clinical trial
- Internal medicine
- Oncology
No related works found for this paper.